about
Epidemiology of Plasmodium vivax Malaria in PeruEffects of point mutations in Plasmodium falciparum dihydrofolate reductase and dihydropterate synthase genes on clinical outcomes and in vitro susceptibility to sulfadoxine and pyrimethamineCharacteristics of Travel-Related Severe Plasmodium vivax and Plasmodium falciparum Malaria in Individuals Hospitalized at a Tertiary Referral Center in Lima, Peru.Field evaluation of a rapid diagnostic test (Parascreen) for malaria diagnosis in the Peruvian Amazon.Clinical and demographic stratification of test performance: a pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis.Non-invasive cytology brush PCR for the diagnosis and causative species identification of American cutaneous leishmaniasis in PeruA FRET-based real-time PCR assay to identify the main causal agents of New World tegumentary leishmaniasisA 3D assessment tool for accurate volume measurement for monitoring the evolution of cutaneous leishmaniasis wounds.Novel low-cost thermotherapy for cutaneous leishmaniasis in PeruPlasmodium vivax malaria at households: spatial clustering and risk factors in a low endemicity urban area of the northwestern Peruvian coast.Quantification of Leishmania (Viannia) Kinetoplast DNA in Ulcers of Cutaneous Leishmaniasis Reveals Inter-site and Inter-sampling Variability in Parasite LoadHotspots of Malaria Transmission in the Peruvian Amazon: Rapid Assessment through a Parasitological and Serological Survey.Association of the Endobiont Double-Stranded RNA Virus LRV1 With Treatment Failure for Human Leishmaniasis Caused by Leishmania braziliensis in Peru and Bolivia.Quantitative Kinetoplast DNA Assessment During Treatment of Mucosal Leishmaniasis as a Potential Biomarker of Outcome: A Pilot Study.Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.Simultaneous infection with Leishmania (Viannia) braziliensis and L. (V.) lainsoni in a Peruvian patient with cutaneous leishmaniasis.Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters.Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasisAssessing malaria transmission in a low endemicity area of north-western Peru.Infection of laboratory-colonized Anopheles darlingi mosquitoes by Plasmodium vivax.Neurological manifestations of human leishmaniasis.Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.Micro-heterogeneity of malaria transmission in the Peruvian Amazon: a baseline assessment underlying a population-based cohort study.Detection and species identification of Leishmania DNA from filter paper lesion impressions for patients with American cutaneous leishmaniasis.Micro-epidemiology and spatial heterogeneity of P. vivax parasitaemia in riverine communities of the Peruvian Amazon: A multilevel analysis.Leishmania OligoC-TesT as a simple, rapid, and standardized tool for molecular diagnosis of cutaneous leishmaniasis in Peru.Accurate and rapid species typing from cutaneous and mucocutaneous leishmaniasis lesions of the New World.Evaluation of the efficacy, safety and acceptability of a fish protein isolate in the nutrition of children under 36 months of age.Predominance of asymptomatic and sub-microscopic infections characterizes the Plasmodium gametocyte reservoir in the Peruvian Amazon.Influence of Leishmania RNA Virus-1 on Pro-Inflammatory Biomarker Expression in a Human Macrophage Model of American Tegumentary Leishmaniasis.High prevalence of very-low Plasmodium falciparum and Plasmodium vivax parasitaemia carriers in the Peruvian Amazon: insights into local and occupational mobility-related transmissionAccelerating to Zero: Strategies to Eliminate Malaria in the Peruvian Amazon.Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation.Regulatory T-Cell Dynamics in Cutaneous and Mucocutaneous Leishmaniasis due to Leishmania braziliensis.Tegumentary leishmaniasis and coinfections other than HIV.A battery of 12 microsatellite markers for genetic analysis of the Leishmania (Viannia) guyanensis complex.Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a studyLone laryngeal leishmaniasisMultiple non-climatic drivers of food insecurity reinforce climate change maladaptation trajectories among Peruvian Indigenous Shawi in the AmazonIs CD1a useful for Leishmaniasis diagnosis in the new world?
P50
Q28355360-DA48464B-E111-462B-A63A-4002841C67F6Q28476005-C0E460DC-86EB-4EFF-B9E6-46B124072C5FQ33426858-6EB3BB59-1A64-4B26-8E0A-2174C3A8FD7DQ33968822-E3D06B72-5318-43FE-B60B-E63A73322BC7Q34024857-13F334AB-CFBB-46E5-8335-4BA365BCB4D4Q34490444-A238C61F-EDF7-4E54-A112-3B33A8ACCFDCQ34542630-3AF97D5A-2D47-46B3-9983-79D5C835E0A4Q34568595-61ADCCAC-201D-4852-BA8C-A782992B373CQ34713385-18850D8E-4728-4B00-A61F-E5545B6E49ABQ35559330-9D515CEF-28FA-478B-ADEA-6A6C95015EBFQ35708519-52C00F36-045F-42BD-955D-3CDA8C205655Q35769213-6FAE4C59-A004-4A74-B972-3B626B016541Q36365284-4C50DAF1-CC06-4272-8F40-C02F44B9D16CQ36455737-356F5DD4-4167-4088-A678-EDD6B5FBA72EQ36591835-18EEB511-86D3-40BC-A937-FE4F5AC5EEFAQ36743902-528D6CCA-443D-4108-83DC-3E71F9F37F76Q37026407-6FECE56D-DC34-4296-880C-70A56B619CB3Q37263833-0F79420B-D6B5-4075-A474-CE91B64DAEEDQ37361179-1A57D044-8362-44E2-8C1B-81F2FC134BF8Q37680691-D477E152-81A9-4688-B356-16096DC02F04Q38119576-B88A3A2A-A633-4BD4-A6BB-37E361DC2E0DQ38320074-2E1645D8-CD79-47B7-897B-EADD2A1C14AEQ38640327-5823F7CA-05CA-4B39-B957-EF84FB34F2DFQ38913244-17ED29D0-4379-4A3D-8F7F-BBE7E3BB96E6Q38932860-779FF910-7A3D-4CA1-9126-6A7E18C3A55AQ38995395-F152328D-62BA-4A45-B63B-5C159737226FQ39010039-BA0A800D-BD54-4090-B17E-8E86909A867DQ39316409-5B597C8C-519C-40F9-8006-346EC19279BFQ39411614-8B390CE9-50AF-4947-9707-0DF5F51F6CE5Q41926518-094F44AF-736A-4DDE-B3D7-60801E55727EQ42379248-FDEDCE01-41B7-4266-9437-FC578E79B760Q46163259-B24BB06B-6C94-43A0-A921-17D7FE2AC32BQ47735229-F177391E-9D21-4AD3-B4B9-8BD85096858CQ50192356-EE6E5E62-F573-48D0-B811-06EAC0462B4FQ54264134-062C687D-54A1-4EF9-94BC-4DF77C476459Q54420952-EBE8BDBA-B30E-4E6E-B615-EB4181FF795FQ56352603-51139B6F-7B36-481F-97EE-386C6E26D3F5Q56797873-5B035E4A-1795-4AB1-86F3-83EC0E49707EQ57459927-B790CAA3-C868-4820-8289-33C14F18FC97Q57471470-747B00E8-F211-4ACD-9B39-7E150B28C769
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Alejandro Llanos-Cuentas
@en
Alejandro Llanos-Cuentas
@nl
type
label
Alejandro Llanos-Cuentas
@en
Alejandro Llanos-Cuentas
@nl
prefLabel
Alejandro Llanos-Cuentas
@en
Alejandro Llanos-Cuentas
@nl
P31
P496
0000-0002-7567-5534